Carlos M. Galmarini

Artificial Intelligence Research Institute — Spain

Biochemistry, Genetics and Molecular Biology · Life Sciences

45h-index10.0kcitations319works0.32yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

RNA modifications and cancer(55), Sarcoma Diagnosis and Treatment(33), Lung Cancer Treatments and Mutations(26), Microtubule and mitosis dynamics(23), Cancer-related Molecular Pathways(23)

Publications316 total

PROCC: a predictive score to identify KRAS wild type metastatic colorectal cancer patients who are likely to obtain survival benefit from panitumumab treatment
British Journal of Cancer·2025
Hereditary Angioedema Diagnosis Evaluation Score (HADES): A Clinical Scoring for Predicting Hereditary Angioedema
Journal of Allergy and Clinical Immunology·2025Open Access
Hereditary angioedema diagnosis evaluation score (HADES): A new clinical scoring system for predicting hereditary angioedema with C1 inhibitor deficiency
Journal of Allergy and Clinical Immunology Global·2025Open Access
PROCC: a predictive score to identify KRAS wild type metastatic colorectal cancer patients who are likely to benefit from panitumumab treatment
2024Open Access
P-68 LIVGUARD, A DEEP NEURAL NETWORK FOR CIRRHOSIS DETECTION IN LIVER ULTRASOUND (USD) IMAGES
Annals of Hepatology·2024Open Access
Development and validation of MOSPROC, an easily applicable predictive score of mortality for patients with prostate cancer.
Journal of Clinical Oncology·2024· 2 cited
Identification of genes related to PD-L1 expression in non-small cell lung cancer (NSCLC) tumor samples by GFPrint, a machine learning framework (MLF).
Journal of Clinical Oncology·2024
Supplementary Figure legends from Lurbinectedin Specifically Triggers the Degradation of Phosphorylated RNA Polymerase II and the Formation of DNA Breaks in Cancer Cells
2023Open Access
Supplementary Figure 1 from Trabectedin and Its C Subunit Modified Analogue PM01183 Attenuate Nucleotide Excision Repair and Show Activity toward Platinum-Resistant Cells
2023Open Access
Supplementary information from The Antitumor Drugs Trabectedin and Lurbinectedin Induce Transcription-Dependent Replication Stress and Genome Instability
2023Open Access
Supplementary Figure 1 from Lurbinectedin Specifically Triggers the Degradation of Phosphorylated RNA Polymerase II and the Formation of DNA Breaks in Cancer Cells
2023Open Access
Supplementary Figure 4 from Lurbinectedin Specifically Triggers the Degradation of Phosphorylated RNA Polymerase II and the Formation of DNA Breaks in Cancer Cells
2023Open Access
Data from Trabectedin and Its C Subunit Modified Analogue PM01183 Attenuate Nucleotide Excision Repair and Show Activity toward Platinum-Resistant Cells
2023Open Access
Figure S5 from The Antitumor Drugs Trabectedin and Lurbinectedin Induce Transcription-Dependent Replication Stress and Genome Instability
2023Open Access
Supplementary Methods, SupplementaryTables 1-2, and Supplementary Figures 1-7 from MI130004, a Novel Antibody–Drug Conjugate Combining Trastuzumab with a Molecule of Marine Origin, Shows Outstanding <i>In Vivo</i> Activity against HER2-Expressing Tumors
2023Open Access
Data from The Antitumor Drugs Trabectedin and Lurbinectedin Induce Transcription-Dependent Replication Stress and Genome Instability
2023Open Access
Supplementary Figure 4 from Lurbinectedin Specifically Triggers the Degradation of Phosphorylated RNA Polymerase II and the Formation of DNA Breaks in Cancer Cells
2023Open Access
Figure S2 from The Antitumor Drugs Trabectedin and Lurbinectedin Induce Transcription-Dependent Replication Stress and Genome Instability
2023Open Access
Data from Trabectedin and Its C Subunit Modified Analogue PM01183 Attenuate Nucleotide Excision Repair and Show Activity toward Platinum-Resistant Cells
2023Open Access
Data from Lurbinectedin Specifically Triggers the Degradation of Phosphorylated RNA Polymerase II and the Formation of DNA Breaks in Cancer Cells
2023Open Access
page 1 of 16Next →

Frequent Co-authors

Charles Dumontet(16), Maurizio D’Incalci(11), Emeline Cros(8), John R. Mackey(7), Lars Petter Jordheim(7), Roberta Frapolli(6), Paola Allavena(6), Xavier Thomas(5), Federico Gago(5), Pablo Avilés(5), Carmen Cuevas(5), Eugenio Erba(4), Juan Fernando Martínez-Leal(4), Luis García‐Fernández(4), Sarah Uboldi(3), Luca Beltrame(3), Sergio Marchini(3), Roberta Sanfilippo(3), Paolo G. Casali(3), Alberto Mantovani(3)